Carmot Therapeutics develops next‑generation GLP‑1 and dual GLP‑1/GIP receptor agonists that use biased signaling to minimize β‑arrestin recruitment, reducing receptor desensitization and extending drug activity. Its pipeline includes a once‑weekly injectable (CT‑388), a Phase 2 GLP‑1/GIP candidate for overweight/obesity with type 1 diabetes (CT‑868), and an oral daily GLP‑1 small‑molecule (CT‑996), all aimed at delivering stronger glycemic control, greater weight loss, and improved tolerability for metabolic disease patients.
Funding
Funding not disclosed
Founders
Product
Problem
Current therapies for obesity and diabetes often rely on conventional GLP‑1 agonists that can cause receptor desensitization, require frequent dosing, and may have limited efficacy across patient sub‑populations.
Solution
Carmot Therapeutics is creating a portfolio of next‑generation GLP‑1 and dual GLP‑1/GIP receptor agonists that employ biased signaling to minimize β‑arrestin recruitment, thereby reducing receptor internalization and prolonging pharmacologic activity. The program includes a once‑weekly injectable (CT‑388), a multi‑center Phase 2 candidate for overweight/obesity with type 1 diabetes (CT‑868), and an oral small‑molecule GLP‑1 agonist (CT‑996) designed for daily dosing. By leveraging biased agonism, these molecules aim to deliver stronger glycemic control, greater weight loss, and improved tolerability compared with existing treatments. Ongoing Phase 1‑2 clinical trials evaluate safety, pharmacokinetics, and efficacy across overweight, obese, type 1 and type 2 diabetes populations. Successful candidates could expand therapeutic options for patients who need more durable and convenient metabolic disease management.
Target Audience
Primary customers are pharmaceutical partners and biotech investors seeking advanced metabolic therapeutics, as well as clinicians treating patients with obesity, type 1 diabetes, and type 2 diabetes who require more effective and convenient treatment options.
Features
- Dual GLP‑1/GIP receptor agonist (CT‑388) with weekly subcutaneous administration and minimal β‑arrestin recruitment
- GLP‑1/GIP agonist (CT‑868) targeting overweight/obesity and type 1 diabetes in a Phase 2 multi‑center trial
- Oral small‑molecule GLP‑1 agonist (CT‑996) delivering daily dosing while maintaining biased signaling
- Biased agonism strategy to reduce receptor desensitization and extend drug efficacy
- Clinical development programs spanning Phase 1b to Phase 2 with robust safety and pharmacokinetic assessments
- Designed for strong cAMP signaling to achieve potent glycemic control and weight reduction